Overview. Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It is an important case where the distinction between “an FDA-approved pharmaceutical product exists” and “NuePharma’s research material is that product” genuinely matters, so it is stated plainly here.
Molecule / class. Tesamorelin is a GHRH analogue — a synthetic peptide engineered to mimic the activity of naturally occurring growth hormone-releasing hormone.
Mechanism under investigation. GHRH acts on the GHRH receptor, primarily in the pituitary gland, to stimulate the release of growth hormone (GH). Growth hormone in turn stimulates production of insulin-like growth factor 1 (IGF-1), largely in the liver; together, the GH/IGF-1 axis is a well-studied regulatory pathway involved in metabolism and body composition, among other functions.
Why the pathway is researched. Because the GH/IGF-1 axis affects fat and lean tissue distribution and metabolism broadly, GHRH analogues have been studied for conditions involving abnormal fat distribution and for other GH-axis-related research questions.
Regulatory status — read carefully. Tesamorelin is the active ingredient in an FDA-approved pharmaceutical product (marketed as EGRIFTA and its later formulations). That approval is for a specific, narrow indication: the reduction of excess visceral abdominal fat in HIV-infected adult patients with lipodystrophy, first approved in 2010 based on clinical trials in patients with that specific condition. It is not approved for general or cosmetic use, and is not approved for use in people without that diagnosis.
NuePharma’s material is not that approved product. NuePharma’s Tesamorelin listing is an unapproved research-use material, supplied for laboratory research only — not the approved pharmaceutical product, not manufactured or distributed under that product’s approval, and not intended for the approved product’s clinical use or any other human or veterinary use. The existence of an approved indication for tesamorelin as a molecule does not extend any approval to this research material.
What remains unknown, in a research context. Effects and safety profiles outside the specific approved population and indication are a separate, ongoing research question from what supported the original approval.
NuePharma product information. NuePharma’s Tesamorelin listing is 20 mg per vial, supplied lyophilized, for research use only.